Pediatrix Medical
MD
25.83
-0.17
-0.65%
Pediatrix Medical
US · MD
#2735 by market cap
Listed 1970
25.83
-0.17
-0.65%
Live - 5344 symbols - heartbeat 532s ago
· 2026-10-07 19:54
After-hours
25.83
0.00%
- Market cap
- 2.10B
- P/E (TTM)i
- 12.36
- P/Bi
- 2.38
- EPSi
- 1.94
- Div yieldi
- 0.00%
- 52W posi
- 83%
Reader sentiment
Are you bullish or bearish on MD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.21, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -4.92% YoY
Margins
- Gross margin
- 25.80%
- Operating margin
- 12.07%
- Net margin
- 8.64%
Key ratios & quality
- Enterprise valuei
- 2.21B
- PEG ratioi
- 0.35
- Altman Z-Scorei
- 2.21
PEG uses trailing P/E against the 3-year net income growth rate (35.60%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.72B | 1.78B | 1.73B | 1.91B | 1.97B | 1.99B | 2.01B | 1.91B |
| Gross profit | 504.96M | 503.09M | 449.32M | 513.24M | 467.03M | 421.57M | 454.34M | 493.70M |
| Selling & admin expenses | 232.22M | 244.51M | 248.95M | 263.36M | 231.40M | 227.54M | 238.44M | 240.79M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 248.39M | 232.65M | 171.93M | 217.74M | 200.00M | 157.85M | 183.68M | 231.09M |
| Pretax profit | 166.21M | 58.78M | 7.15M | 135.23M | 81.37M | -48.36M | -101.34M | 216.43M |
| Tax | 44.69M | 16.58M | 16.73M | 27.24M | 18.81M | 12.05M | -2.27M | 51.04M |
| Net profit | 268.63M | -1.50B | -796.49M | 130.94M | 66.33M | -60.41M | -99.07M | 165.39M |
| Basic EPS | 3 | -18 | -10 | 2 | 1 | -1 | -1 | 2 |
| Diluted EPS | 2.93 | -17.94 | -9.55 | 1.53 | 0.79 | -0.73 | -1.19 | 1.94 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 458.36M | 468.84M | 492.88M | 493.77M | 476.20M | 487.78M |
| Gross profit | 102.64M | 124.73M | 140.35M | 125.98M | 112.96M | 132.47M |
| Selling & admin expenses | 58.60M | 55.71M | 60.79M | 65.68M | 60.27M | 61.29M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 38.71M | 63.70M | 74.01M | 54.67M | 46.58M | 65.40M |
| Pretax profit | 28.09M | 54.97M | 87.78M | 45.60M | 38.84M | 54.00M |
| Tax | 7.35M | 15.71M | 16.07M | 11.91M | 9.27M | 14.16M |
| Net profit | 20.74M | 39.26M | 71.71M | 33.68M | 29.57M | 39.84M |
| Basic EPS | 0 | 0 | 1 | 0 | 0 | 1 |
| Diluted EPS | 0.24 | 0.46 | 0.84 | 0.40 | 0.36 | 0.49 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 659.98M | 731.51M | 1.55B | 840.56M | 427.99M | 483.45M | 639.61M | 763.51M |
| Cash & ST investments | 47.41M | 182.38M | 1.23B | 487.11M | 103.06M | 177.74M | 348.51M | 499.72M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 5.94B | 4.15B | 3.35B | 2.72B | 2.35B | 2.22B | 2.15B | 2.25B |
| Total current liabilities | 502.76M | 541.82M | 444.34M | 427.37M | 426.98M | 388.95M | 434.11M | 458.91M |
| Short-term debt | 253.00K | 18.25M | 21.15M | 22.17M | 36.49M | 35.99M | 33.25M | 38.40M |
| Long-term debt | 1.97B | 1.73B | 1.73B | 1.00B | 627.65M | 611.59M | 593.57M | 568.95M |
| Total liabilities | 2,849,597,000.00 | 2,646,905,000.00 | 2,600,231,000.00 | 1,825,854,000.00 | 1,456,255,000.00 | 1,370,749,000.00 | 1,387,762,000.00 | 1,380,842,000.00 |
| Total equity | 3.09B | 1.50B | 747.72M | 896.69M | 891.63M | 849.06M | 764.94M | 865.85M |
| Retained earnings | 2.09B | 510.13M | -286.35M | -155.39M | -89.06M | -149.47M | -248.54M | -83.15M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 491.67M | 613.05M | 717.20M | 763.51M | 587.03M | 660.14M |
| Cash & ST investments | 219.18M | 348.33M | 463.10M | 499.72M | 328.97M | 404.20M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.99B | 2.10B | 2.20B | 2.25B | 2.07B | 2.13B |
| Total current liabilities | 271.05M | 341.04M | 392.55M | 458.91M | 442.64M | 501.58M |
| Short-term debt | 34.30M | 35.73M | 37.57M | 38.40M | 204.31M | 198.42M |
| Long-term debt | 590.48M | 583.86M | 577.17M | 568.95M | 398.35M | 398.06M |
| Total liabilities | 1,204,291,000.00 | 1,268,347,000.00 | 1,308,739,000.00 | 1,380,842,000.00 | 1,191,719,000.00 | 1,249,365,000.00 |
| Total equity | 789.19M | 833.75M | 890.67M | 865.85M | 878.58M | 880.98M |
| Retained earnings | -227.80M | -188.54M | -116.84M | -83.15M | -53.58M | -13.74M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 313.71M | 357.71M | 204.62M | 76.74M | 166.94M | 137.33M | 206.57M | 271.09M |
| Depreciation & amortization | 24.36M | 25.93M | 28.44M | 32.15M | 35.64M | 36.17M | 32.23M | 21.83M |
| Free cash flow | 296.59M | 338.44M | 175.83M | 44.49M | 137.23M | 104.00M | 184.55M | 252.63M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -285.90M | -134.02M | -1.48M | 2.13M | -83.12M | 3.99M | 1.94M | -83.50M |
| Ending cash balance | 40.77M | 107.87M | 1.12B | 387.39M | 9.82M | 73.26M | 229.94M | 375.24M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -117.46M | 137.17M | 137.29M | 114.10M | -129.85M | 125.32M |
| Depreciation & amortization | 5.33M | 5.31M | 5.55M | 5.63M | 6.12M | 5.78M |
| Free cash flow | -120.78M | 132.65M | 131.95M | 108.82M | -136.09M | 123.94M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -907.00K | 967.00K | -20.17M | -63.39M | -20.91M | -41.67M |
| Ending cash balance | 98.98M | 224.73M | 340.06M | 375.24M | 205.78M | 288.88M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 8.73 | -65.30 | -70.91 | 15.93 | 7.42 | -6.94 | -12.28 | 20.28 |
| ROA %i | 4.55 | -29.71 | -21.26 | 4.31 | 2.62 | -2.65 | -4.53 | 7.52 |
| ROIC %i | 6.68 | -33.10 | -24.38 | 8.23 | 5.42 | -1.72 | -3.98 | 13.18 |
| 5-year avg ROE %i | 12.06 | -3.75 | -20.80 | -20.11 | -20.83 | -23.96 | -13.35 | 4.88 |
| EBIT margin %i | 12.55 | -31.95 | 6.78 | 10.67 | 6.14 | -0.32 | -3.01 | 13.19 |
| FCF / sales %i | 6.61 | 8.96 | 10.14 | 2.33 | 6.96 | 5.21 | 9.17 | 13.20 |
| Current ratioi | 1.31 | 1.35 | 3.49 | 1.97 | 1.00 | 1.24 | 1.47 | 1.66 |
| Quick ratioi | 1.10 | 1.14 | 3.31 | 1.88 | 0.94 | 1.18 | 1.43 | 1.62 |
| Debt / assetsi | 33.26 | 43.25 | 53.90 | 39.15 | 30.54 | 31.61 | 30.77 | 28.25 |
| LT debt / equityi | 63.94 | 118.40 | 238.60 | 116.42 | 76.33 | 78.40 | 82.24 | 68.86 |
| Interest coveragei | 5.16 | -9.40 | 1.06 | 2.97 | 3.05 | -0.15 | -1.49 | 7.02 |
| Revenue CAGR (3Y) %i | -14.74 | -17.62 | -18.92 | 3.51 | 3.48 | 4.78 | 1.74 | -0.99 |
| Net income CAGR (3Y) %i | -7.22 | -- | -- | -21.30 | -- | -- | -- | 35.60 |
| FCF CAGR (3Y) %i | -4.60 | -5.77 | -28.71 | -46.87 | -25.98 | -16.06 | 60.68 | 22.56 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -10.01 | 14.27 | 19.98 | 20.28 | 20.89 | 20.39 |
| ROA %i | -3.96 | 5.37 | 7.59 | 7.52 | 8.57 | 8.26 |
| ROIC %i | -3.33 | 9.66 | 12.99 | 13.18 | 13.62 | 13.48 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -2.11 | 9.26 | 12.54 | 13.19 | 13.58 | 13.35 |
| FCF / sales %i | 9.83 | 11.70 | 14.22 | 13.20 | 12.29 | 11.72 |
| Current ratioi | 1.81 | 1.80 | 1.83 | 1.66 | 1.33 | 1.32 |
| Quick ratioi | 1.74 | 1.74 | 1.78 | 1.62 | 1.28 | 1.28 |
| Debt / assetsi | 32.87 | 30.90 | 29.20 | 28.25 | 30.42 | 29.10 |
| LT debt / equityi | 78.69 | 73.62 | 67.89 | 68.86 | 48.42 | 47.85 |
| Interest coveragei | -1.06 | 4.72 | 6.53 | 7.02 | 7.48 | 7.63 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Physician services including newborn, maternal-fetal, and other pediatric subspecialty care100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.